AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.37 -0.24 (-1.90%)

Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >

AbCellera (ABCL) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

Via The Motley Fool

Topics Earnings Intellectual Property

Here are the top movers in Monday's session. ↗

August 10, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

August 10, 2026

Via Chartmill

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial ↗

August 10, 2026

AbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot...

Via MarketBeat

AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS ↗

August 05, 2026

Via Chartmill

AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall ↗

February 24, 2026

Via Chartmill

Topics Intellectual Property

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 07, 2026

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report...

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

August 07, 2026

Via Chartmill

AbCellera Biologics Q2 Earnings Call Highlights ↗

August 05, 2026

AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot...

Via MarketBeat

Topics Earnings

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗

June 04, 2026

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said...

Via MarketBeat

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

AbCellera Biologics Q1 Earnings Call Highlights ↗

May 11, 2026

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued...

Via MarketBeat

Topics Earnings

AbCellera (ABCL) Q1 2026 Earnings Transcript ↗

May 11, 2026

AbCellera (ABCL) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Stay updated with the stocks that are on the move in today's after-hours session. ↗

May 11, 2026

Via Chartmill

CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It ↗

March 26, 2026

The CRA confirmed $7,000 in TFSA room for 2026. Here's why AbCellera Biologics could be one of the smartest growth stocks to put that money to work in right now.

Via The Motley Fool

These stocks are moving in today's after hours session ↗

February 24, 2026

Via Chartmill

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗

November 07, 2025

Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April.

Via Benzinga

Topics Artificial Intelligence

AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗

November 06, 2025

AbCellera's Q3 2025 results show revenue beat estimates, but the net loss widened, causing a negative after-hours stock reaction.

Via Chartmill

AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗

November 06, 2025

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto...

Via Benzinga

Topics Artificial Intelligence

Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗

October 02, 2025

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.

Via Benzinga

Topics Stocks

Why Did AbCellera's Stock Jump Over 7% After Hours? ↗

October 02, 2025

AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 18, 2025

Via Benzinga

Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts ↗

August 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 08, 2025

Via Benzinga

AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript ↗

August 08, 2025

Via The Motley Fool

Topics Earnings

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

August 07, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗

July 21, 2025

Via Benzinga

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today ↗

June 02, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.